Trial Profile
A phase Ib, open-label, pharmacokinetics and safety study of IN-006 (regdanvimab for nebulization) versus intravenous regdanvimab in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Regdanvimab (Primary) ; Regdanvimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Inhalon Biopharma
- 20 Mar 2024 Results published in an Inhalon Biopharma Media Release
- 18 Mar 2024 According to Inhalon Biopharma Media Release, today announced initial results from Phase 1b study that directly compares the distribution and retention of antibodies throughout the human respiratory tract following both inhaled and intravenous (IV) delivery.
- 27 Aug 2023 Status changed from active, no longer recruiting to completed.